Climb Bio, Inc.

NasdaqGM:CLYM Stok Raporu

Piyasa değeri: US$502.5m

Climb Bio Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Aoife Brennan

İcra Kurulu Başkanı

US$2.9m

Toplam tazminat

CEO maaş yüzdesi22.91%
CEO görev süresi1.9yrs
CEO sahipliği0.1%
Yönetim ortalama görev süresiless than a year
Yönetim Kurulu ortalama görev süresi1.7yrs

Son yönetim güncellemeleri

Recent updates

Seeking Alpha • Apr 16

Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway

Summary Climb Bio, Inc. maintains a Buy rating, driven by budoprutug’s strong phase 1b and long-term data in primary membranous nephropathy [pMN]. CLYM’s phase 2 PrisMN trial in pMN, with initial data expected 2H 2026, is a key catalyst; expansion into SLE and ITP offers additional upside. Budoprutug’s versatility, including a subcutaneous formulation and broad B-cell depletion, positions CLYM for competitive advantage in autoimmune disorders. With $160.7M in cash, CLYM is funded into 2028, reducing near-term dilution risk and supporting execution on multiple clinical milestones. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 07

Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 23

Eliem Therapeutics: Recent Strategic Pipeline Restructuring

Summary Eliem Therapeutics, founded in 2019, shifted focus to autoimmune diseases with the acquisition of Tenet Medicines and its lead molecule, budoprutug. Budoprutug targets CD19-positive B cells, aiming to treat SLE, ITP, and MN by reducing pathogenic autoantibodies and improving disease symptoms. Early clinical trials for MN showed promising results, with 60% of patients achieving complete remission of proteinuria, supporting further development. Despite a decent market cap and cash reserves, ELYM's early-stage status and single-molecule focus make it a cautious watch rather than an immediate investment. Read the full article on Seeking Alpha
Seeking Alpha • Jun 28

Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock Value

Summary Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia. Acquisition of Tenet Medicines and $120 million private placement agreement provide funding for operations into 2027, with cash on hand at $220 million. Read the full article on Seeking Alpha
Analiz Makalesi • Feb 01

Here's Why We're Not Too Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Jun 24

We Think Eliem Therapeutics (NASDAQ:ELYM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analiz Makalesi • Mar 08

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Nov 18

We're Not Very Worried About Eliem Therapeutics' (NASDAQ:ELYM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 15

Eliem Therapeutics GAAP EPS of -$0.56 misses by $0.09

Eliem Therapeutics press release (NASDAQ:ELYM): Q2 GAAP EPS of -$0.56 misses by $0.09. Cash, cash equivalents and short- and long-term marketable securities was $134.7M as of June 30, 2022, as compared to $161.4M as of December 31, 2021. With the discontinuation of ETX-810, the company’s current cash, cash equivalents and short- and long-term marketable securities are now expected to fund operations into 2025.
Seeking Alpha • Aug 02

Eliem to discontinue development of lead asset as mid-stage pain trial fails

Clinical-stage biotech Eliem Therapeutics (NASDAQ:ELYM) announced on Tuesday that the company decided to discontinue further development of its lead asset ETX-810 after the failure of a mid-stage trial for the candidate in lumbosacral radicular pain (LSRP). The primary endpoint of the 148-patient Phase 2a trial was the change in the weekly average of the daily pain score from baseline to week 4, measured using the Pain Intensity Numerical Rating Scale (PI-NRS). The results indicated that ETX-810 did not indicate a statistically significant separation from the placebo in the primary endpoint, according to the company. The results were similar to previously disclosed data from another Phase 2 trial in diabetic peripheral neuropathic pain (DPNP) which also indicated a lack of separation for the treatment arm compared to the placebo, the company said.
Seeking Alpha • Jul 11

SVB Leerink cuts PT on Eliem Therapeutics, reaffirms Outperform rating

SVB Leerink on Monday cut its price target on Eliem Therapeutics (NASDAQ:ELYM) to $9 from $13. The new PT - based on an SOTP analysis that forecasts cash flows into early 2040s, with 11% discount rate - implies potential upside of 142.6% to ELYM's last close. The brokerage reiterated its Outperform rating, in-line with sell-side rating of Strong Buy. "Given the decreased bioavailability of ETX-155 observed in the phase 1b interim data readout in photosensitive epilepsy, we lowered our POS for all ETX-155 programs, which resulted in our PT moving to $9," analyst Marc Goodman wrote in a note to clients. "We still expect data from ETX-810 in lumbosacral radicular pain in Q3, although expectations are low after the failed phase 2 study in diabetic peripheral neuropathy," he added. ELYM stock, which fell as much as 5.4% on Monday, has declined 67.3% YTD.

CEO Tazminat Analizi

Aoife Brennan'un ücretlendirmesi Climb Bio'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$53m

Dec 31 2025US$3mUS$670k

-US$60m

Sep 30 2025n/an/a

-US$51m

Jun 30 2025n/an/a

-US$47m

Mar 31 2025n/an/a

-US$93m

Dec 31 2024US$6mUS$330k

-US$74m

Tazminat ve Piyasa: Aoife 'ın toplam tazminatı ($USD 2.92M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 2.72M ).

Tazminat ve Kazançlar: Aoife 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Aoife Brennan (49 yo)

1.9yrs
Görev süresi
US$2,922,223
Tazminat

Dr. Aoife M. Brennan, M.D. M.B., Ch B., BAO, MMSc, MRCPI, is CEO, President at Climb Bio, Inc. (formerly known as Eliem Therapeutics, Inc.) and serves as its Director since June 2024 and served as its Inte...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Aoife Brennan
CEO, President & Directorno dataUS$2.92m0.10%
$ 506.3k
Susan Altschuller
CFO & Principal Accounting Officerless than a yearUS$1.53mVeri yok
Perrin Wilson
Chief Business Officer1.3yrsUS$1.59m0%
$ 0
Adam Villa
Senior VP of Technical Operationsless than a yearVeri yokVeri yok
Chandra Adams
VP, General Counsel & Secretary1yrVeri yokVeri yok
Ashley Jones
Senior VP of People & Workforce Strategyless than a yearVeri yokVeri yok
Janaki Subramanyam
VP & Head of Regulatory Affairsno dataVeri yokVeri yok
Edgar Charles
Chief Medical Officerless than a yearVeri yokVeri yok
Theresa Donegan
Vice President & Head of Qualityno dataVeri yokVeri yok
0.8yrs
Ortalama Görev Süresi
46yo
Ortalama Yaş

Deneyimli Yönetim: CLYM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Aoife Brennan
CEO, President & Director1.9yrsUS$2.92m0.10%
$ 506.3k
Douglas Williams
Independent Chairman of the Board1.5yrsUS$205.33k0%
$ 0
Kimberlee Drapkin
Independent Director1.2yrsUS$170.57k0%
$ 0
Andrew Levin
Directorno dataUS$79.12k0%
$ 0
Alexander Cumbo
Independent Director1.2yrsUS$168.67k0%
$ 0
Stephen Thomas
Director1.9yrsUS$79.12k0.32%
$ 1.6m
Judith Dunn
Independent Director5.3yrsUS$89.75k0%
$ 0
1.7yrs
Ortalama Görev Süresi
54yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: CLYM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 05:51
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Climb Bio, Inc. 16 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Colleen KusyBaird
Mayank MamtaniB. Riley Securities, Inc.
Julian HarrisonBTIG